Stifel initiated coverage of Edgewise Therapeutics (EWTX) with a Hold rating and $30 price target The firm says that while Edgewise has “very ...

Paul Matteis, an analyst from Stifel Nicolaus, has initiated a new Hold rating on Edgewise Therapeutics (EWTX).Invest with Confidence: Follow ...

Edgewise Therapeutics stock opened at $25.33 on Friday. Edgewise Therapeutics has a 52 week low of $9.00 and a 52 week high of $38.12. The firm’s 50-day simple moving average is $30.54 and its ...

January 13, 2025--(BUSINESS WIRE)--Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided recent corporate updates and highlighted upcoming ...

Investors in Edgewise Therapeutics Inc (Symbol: EWTX) saw new options become available today, for the December 19th expiration. One of the key inputs that goes into the price an option buyer is ...

Texas Longhorns quarterback Arch Manning on Monday shot down rumors he had made plans to enter the transfer portal at the end of the season as the team prepared for its next College Football ...

We can readily understand why investors are attracted to unprofitable companies. For example, Edgewise Therapeutics (NASDAQ:EWTX) shareholders have done very well over the last year, with the share ...

This week is an ideal time to take stock of what you really need for contentment. Sometimes that requires a pause, a step back, a huge breath. Other times you can find the clarity you’re seeking ...

Saint-Gobain is not responsible for, and expressly disclaims liability for, damages of any kind arising out of use, reference to or reliance on any information contained on this site. No guarantee ...

Arch Capital Group (ACGL) closed at $91.38 in the latest trading session, marking a -1.05% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 0.22% for the day.

Edgewise Therapeutics (NASDAQ:EWTX) is building itself up as a good long-term biotech to hang onto. Especially, when you consider that it was able to report positive results from its phase 2 ...